Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in biocon

Biocon Elevates Siddharth Mittal To CEO, Joint MD's Position

Mittal takes over from Arun Chandavarkar who retired on November 30 after 29 years of contribution to the company's evolution.

Read More

US FDA Approves Biocon’s sBLA For Pegfilgrastim New Manufacturing Facility

With the approval of this additional facility, Biocon Biologics and Mylan will be able to address the growing needs of patients for biosimilar Pegfilgrastim in the US

Read More

Biocon Pulls Application For EU Approval Of Two Drugs

Biocon will re-submit the applications for breast cancer drug Trastuzumab and Pegfilgrastim, which cuts infection risk in patients undergoing chemotherapy, after the European Medicines Agency completes the inspection

Read More

Mylan-Biocon Combine’s Generic Insulin May Hit Market Sooner

Insulin glargin is a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar.

Read More

The First Gen Biotech Legend

Kiran Mazumdar-Shaw, CMD, Biocon is a role model and inspiration for many budding entrepreneurs

Read More

To Many More Healthy Days To Us!

With more focus on understanding diseases at a cellular and genetic level, our life expectancy is increasing

Read More

Biocon's Novel Diabetes Education Initiative Gets Award

ABIDE has been conferred with the 'Award of Recognition' for its benefits by the prestigious Research Society for the Study of Diabetes in India

Read More

Biocon, Mylan Say Regulatory Submission For Insulin Glargine Accepted For Review

The two companies, which have co-developed insulin glargine, said they look forward to offering another insulin treatment option for diabetic patients

Read More

India Witnessing 'Jobless' Growth: Kiran Mazumdar-Shaw

The chairperson and MD of Biocon Ltd says the country is witnessing jobless growth because of poor industrial and agricultural policies

Read More

Future Jobs To Be Driven By Digital Tech: Kiran Mazumdar-Shaw

'They (jobs of the future) are likely to be personalised and self-employment based. Probably the future will comprise multiplexed microjobs rather than today's one employment at a time model'

Read More

Biocon Names Suresh Subramanian As Head Of Branded Formulations Biz

Suresh has over 30 years of experience in the pharmaceuticals market, having worked in India and Thailand for MNCs such as GlaxoSmithKline, Novartis, AstraZeneca and Pfizer

Read More

Licence Raj Replaced By Time-consuming Approval Raj, Says Biocon CMD Kiran Mazumdar-Shaw

India may have created a competitive market by abolishing licence raj, but it has been replaced by an equally time-consuming "approval raj" fraught with potential corruption, Biocon CMD Kiran Mazumdar-Shaw has said

Read More

Biocon Q1 Net Up 17% At Rs 147 Crore

Biotechnology major Biocon has posted 17 per cent rise in net profit at Rs 147 crore for the first quarter ended June 30 on the back of robust growth in segments like biologics and branded formulations.

Read More

Mylan, Biocon Announce Regulatory Submission Accepted For Review By EMA

Biocon and Mylan are exclusive partners on a broad portfolio of biosimilars and generic insulin analogs

Read More

Biocon Signs Rh-insulin Co-development Agreement With Mexican Co

Biocon is currently one of the large insulins producers in Asia and it has a range of products including rh-Insulin (Insugen) and Insulin Glargine (Basalog) in India and several emerging markets.

Read More